GEFISTERIS 250: Uses, Side effect, Pictures, Dosage, ETC.....

GEFISTERIS 250

Gefitinib (250mg)

Gefisteris 250 is a medication containing Gefitinib 250mg per tablet. 

Key Features of Gefisteris 250

• Gefitinib Content: Each tablet of Gefisteris 250 contains 250mg of Gefitinib.
• Targeted Therapy: Gefitinib targets and inhibits the epidermal growth factor receptor (EGFR), which is overactive in some types of cancer cells.
• Indication: Gefisteris 250 is indicated for the first-line treatment of metastatic NSCLC with EGFR mutations.

Benefits of Gefitinib (250mg)

• Cancer Control: Effective in slowing down or stopping the growth of cancer cells in NSCLC with EGFR mutations.
• Improved Survival: Gefisteris 250 has been shown to prolong progression-free survival and overall survival in eligible patients.
• Quality of Life: By controlling cancer progression, Gefitinib can improve symptoms and enhance quality of life.

Mechanism of Action

• EGFR Inhibition: Gefitinib binds to EGFR, preventing its activation and downstream signaling pathways that promote cell growth.
• Cell Cycle Arrest: By interfering with cell cycle progression, Gefitinib induces apoptosis (cell death) in cancer cells.
• Genetic Testing: Patients are typically tested for EGFR mutations before starting Gefitinib to ensure its efficacy.

Dosage and Administration

• Recommended Dosage: The standard dose of Gefisteris 250 is 250mg taken orally once daily.
• Timing: It can be taken with or without food, but consistency in timing is important for optimal effectiveness.
• Consultation: Patients should consult their oncologist for proper dosage instructions and monitoring.

Potential Side Effects

• Common Side Effects: Rash, diarrhea, nausea, and fatigue are common but manageable with supportive care.
• Less Common Reactions: Interstitial lung disease, liver toxicity, and gastrointestinal perforation may occur rarely.
• Monitoring: Regular medical check-ups and monitoring of liver function and lung health are essential during Gefitinib treatment.

Conclusion Gefisteris 250, containing Gefitinib (250mg), is an important medication for the treatment of NSCLC with EGFR mutations. Its targeted mechanism of action and proven efficacy make it a valuable option in oncology.A team of highly skilled professionals in the pharmaceutical field established Steris Healthcare Pvt Ltd in February 2018. Sterispharma is a certified pharmaceutical company by WHO, GMP, and ISO, situated in Navi Mumbai. It is dedicated to delivering high-quality medications at competitive prices to customers across India, adhering to WHO's stringent standards. Through Steris's online pharmacy, customers can conveniently purchase medicines and receive home delivery. Our primary objective at Steris is to offer a comprehensive range of healthcare products to fulfill the diverse requirements of the healthcare industry. Steris is committed to meeting the healthcare sector's demands, whether it's specialized treatments, medications for rare diseases, or essential pharmaceuticals. The range of Steris healthcare products caters to various medical needs, including Cardiology, Asthma, Respiratory, Nasal, Diabetes, Endocrinology, Gastrology, Orthopedics, Anti-infective/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental, and Dermatology.  

 For further information: 

 EMAIL:  info@sterispharma.com  / contact@sterispharma.com

 CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668

  BUY NOW